Open AccessIn vivo molecular imaging of chemokine receptor CXCR 4 expression in patients with advanced multiple myeloma
Author(s) -
PhilippAbbrederis Kathrin,
Herrmann Ken,
Knop Stefan,
Schottelius Margret,
Eiber Matthias,
Lückerath Katharina,
Pietschmann Elke,
Habringer Stefan,
Gerngroß Carlos,
Franke Katharina,
Rudelius Martina,
Schirbel Andreas,
Lapa Constantin,
Schwamborn Kristina,
Steidle Sabine,
Hartmann Elena,
Rosenwald Andreas,
Kropf Saskia,
Beer Ambros J,
Peschel Christian,
Einsele Hermann,
Buck Andreas K,
Schwaiger Markus,
Götze Katharina,
Wester HansJürgen,
Keller Ulrich
Publication year - 2015
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.201404698
Subject(s) - cxcr4 , chemokine receptor , flow cytometry , in vivo , positron emission tomography , pathology , multiple myeloma , chemokine , medicine , cancer research , biology , receptor , immunology , nuclear medicine , microbiology and biotechnology
CXCR 4 is a G‐protein‐coupled receptor that mediates recruitment of blood cells toward its ligand SDF ‐1. In cancer, high CXCR 4 expression is frequently associated with tumor dissemination and poor prognosis. We evaluated the novel CXCR 4 probe [ 68 Ga]Pentixafor for in vivo mapping of CXCR 4 expression density in mice xenografted with human CXCR 4‐positive MM cell lines and patients with advanced MM by means of positron emission tomography ( PET ). [ 68 Ga]Pentixafor PET provided images with excellent specificity and contrast. In 10 of 14 patients with advanced MM [ 68 Ga]Pentixafor PET / CT scans revealed MM manifestations, whereas only nine of 14 standard [ 18 F]fluorodeoxyglucose PET / CT scans were rated visually positive. Assessment of blood counts and standard CD 34 + flow cytometry did not reveal significant blood count changes associated with tracer application. Based on these highly encouraging data on clinical PET imaging of CXCR 4 expression in a cohort of MM patients, we conclude that [ 68 Ga]Pentixafor PET opens a broad field for clinical investigations on CXCR 4 expression and for CXCR 4‐directed therapeutic approaches in MM and other diseases.